To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Journavx

Suzetrigine
Analgesic
Oral Tablet

Journavx is a non‑opioid oral painkiller approved for adults with moderate‑to‑severe acute pain. It blocks sodium‑channel pain signals in the body, relieving pain without addiction risk.

Approval Date
30-Jan-25
NCE-1 Date
30-Jan-29
NCE Date
30-Jan-30
Commercial snapshot

Market performance & projections

Revenue ($M)
60
CAGR (%)
113.56%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
507
2027
590
2028
911
2029
1,248
2030
1,592
2031
1,930
2032
2,277
Molecule profile

Details & specifications

Molecule
Suzetrigine
Innovator
VERTEX PHARMACEUTICALS INC
Dosage Form
Oral Tablet
Strength
50 mg
Therapeutic Category
Analgesic
Usage
To treat moderate to severe acute pain
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?